The Tumor Immunoenvironment (eBook)

Preface  Dmitry I. Gabrilovich IntroductionRole of the immunological environment in cancer initiation, development and progressionAnatoli Malyguine, Viktor Umansky and Michael R. Shurin Part I   Tumor Microenvironment and ImmunoenvironmentThe metastatic microenvironment Shelly Maman and Isaac P. Witz Tumor infiltration by immune cells: pathologic evaluation and a clinical significanceDmitri W. GutkinImmunologic interpretation of cancer biology: impact on clinical outcome Maria Libera Ascierto, Ena Wang and Francesco M Marincola                        Part II  Developmental Characteristics of the Tumor ImmunoEnvironment  Development of antitumor cellular immunityM.J.P. Welters and S.H. van der Burg  The versatile world of inflammatory chemokines in cancerTal Leibovich-Rivkin, Yaeli Lebel-Haziv, Shalom Lerrer, Polina Weitzenfeld and Adit Ben-Baruch Inflammation, Tumor Progression, and Immune SuppressionSuzanne Ostrand-Rosenberg Pleiotropic and differential functions of IL-1a and IL-1b shape the tumor microenvironment and affect the outcome of malignanciesRon N. Apte and Elena Voronov Impact of obesity and aging on the tumor immunoenvironmentAnnie Mirsoian, Gail D. Sckisel, Anthony E. Zamora and William J. Murphy Part III Tumor Escape from Immune Recognition MHC class I antigens and the tumor microenvironmentNatalia Apsirauri, Teresa Cabrera, Angel Garcia-Lora, Francisco Ruiz-Cabello and Federico Garrido Tumor-produced immune regulating factors Mads Hald Andersen, Jürgen C. Becker and Per thor StratenRoles of signaling pathways in cancer cells and immune cells in generation of immunosuppressive tumor-associated microenvironmentsYutaka Kawakami, Tomonori Yaguchi, Hidetoshi Sumimoto, Chie Kudo-Saito, Nobuo Tsukamoto, Tomoko Iwata-Kajihara, Shoko Nakamura, Hiroshi Nishio, Ryosuke Satomi, Asuka Kobayashi, Mayuri Tanaka, Jeong Hoon Park, Hajime Kamijuku, Takahiro Tsujikawa and Naoshi Kawamura T cell malfunction in the tumor environmentEitan YefenofSignaling of tumor-induced immunosuppression of dendritic cellsYong Lu, Jing Yang and Qing Yi Tumor microenvironment may shape the function and phenotype of NK cells through the induction of split anergy and generation of regulatory NK cellsAnahid Jewett and Han-Ching Tseng            Part IV  Immune Regulators in the Tumor ImmunoEnvironment The role of myeloid-derived suppressor cells in cancerJonathan Weiss   Macrophage differentiation and activation states in the tumor microenvironmentJo A. Van Ginderachter  Dendritic cells and cancer: development, dysfunction and therapeutic targetsStephanie K. Watkins and Arthur A. Hurwitz            The role of tumor-associated neutrophils in cancerZvi G. Fridlender Mast cell modulation of the tumor microenvironmentJean Marshall and Sharon OldfordRegulatory T cells in patients with cancerTheresa WhitesideTumor-evoked regulatory B cells as important mediators of cancer escape Catalina Lee-Chang, Monica Bodogai and Arya Biragyn Part V  Tumor Escape and Cancer Immunotherapy  Cancer immunotherapy: Overview in briefPhilipp Beckhove Programming of MDSC: New opportunities for targeted therapyPeter Svider, Shu-Hsia Chen and Andy SikoraTherapeutic targeting regulatory T cells in tumorWei Wang and Weiping ZouChemoImmunoModulation: Focus on myeloid regulatory cellsViktor Umansky and Michael R. Shurin Combining vaccines with therapies that render tumor cells more susceptible to immune mediated killingNishith Singh, James Hodge, Ravi Madan and James L. GulleyProphylactic Cancer VaccinesPamela L. Beatty and Olivera Finn Part VI  Analyzing Immune Responses in Cancer Approaches to Immunologic Monitoring of Clinical TrialsLisa H. Butterfield, Lazar Vujanovic and Angela Pardee  Evaluation of the tumor immunoenvironment in clinical trialsAnatoli Malyguine, Kimberly Dunham, Thomas Sayers and Michael R. Shurin Analysis of Myeloid-derived Suppressor Cells in Patients with CancerPeiyuan Zhu, Yevgeniya V. Segal, Galina V. Shurin and Michael R. ShurinWhen results of T cell immune monitoring match or do not match clinical   outcomes of tumor vaccine trials - what more could and should we measure?Paul V. Lehmann and Srividya Sundararaman